Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL PD 1 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL PD 1 W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Intraperitoneal administration of Dianeal PD-1 with 4.25% dextrose creates an osmotic gradient across the peritoneal membrane, promoting ultrafiltration of fluid and removal of uremic solutes (e.g., urea, creatinine) through diffusion and convection.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal administration; dose individualized based on body size, residual renal function, and dialysis adequacy. Typical regimen: 2-2.5 L instilled into peritoneal cavity for a dwell time of 4-8 hours, 4-5 exchanges per day in continuous ambulatory peritoneal dialysis (CAPD).
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable; dextrose is continuously absorbed and metabolized; elimination half-life depends on glucose utilization rate (2-4 hours in normal state).
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Dextrose is metabolized to CO2 and water; less than 1% excreted unchanged in urine. No biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution